Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Viatris Readies Restasis Launch – So Where Are The Others?
‘No Remaining Legal Or Regulatory Barriers’ Notes F-T-M Viatris
Feb 07 2022
•
By
Dean Rudge
Viatris/Mylan had worked for "nearly a decade" on its ANDA • Source: Alamy
More from Products
More from Generics Bulletin